NASDAQ:PAND

Pandion Therapeutics Competitors

$60.05
0.00 (0.00 %)
(As of 04/1/2021)
Add
Compare
Today's Range
$60.05
Now: $60.05
$60.05
50-Day Range
$25.63
MA: $59.44
$61.63
52-Week Range
$10.28
Now: $60.05
$62.90
VolumeN/A
Average Volume355,921 shs
Market Capitalization$1.77 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pandion Therapeutics (NASDAQ:PAND) Vs. ARWR, GWPH, ASND, TGTX, IONS, and ALLK

Should you be buying PAND stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Pandion Therapeutics, including Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), and Allakos (ALLK).

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Pandion Therapeutics (NASDAQ:PAND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Pandion Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arrowhead Pharmaceuticals021002.83
Pandion Therapeutics02202.50

Arrowhead Pharmaceuticals currently has a consensus target price of $85.3077, suggesting a potential upside of 26.27%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Pandion Therapeutics.

Profitability

This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arrowhead Pharmaceuticals-96.09%-17.37%-15.19%
Pandion TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$87.99 million79.69$-84,550,000.00($0.84)-80.43
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A

Pandion Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Pandion Therapeutics (NASDAQ:PAND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for GW Pharmaceuticals and Pandion Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GW Pharmaceuticals010402.29
Pandion Therapeutics02202.50

GW Pharmaceuticals currently has a consensus target price of $204.0909, suggesting a potential downside of 6.69%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given GW Pharmaceuticals' higher possible upside, research analysts clearly believe GW Pharmaceuticals is more favorable than Pandion Therapeutics.

Profitability

This table compares GW Pharmaceuticals and Pandion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GW Pharmaceuticals-11.05%-7.46%-6.13%
Pandion TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares GW Pharmaceuticals and Pandion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GW Pharmaceuticals$311.33 million22.04$-9,020,000.00($0.24)-912.08
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A

GW Pharmaceuticals has higher revenue and earnings than Pandion Therapeutics.

Institutional and Insider Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GW Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Ascendis Pharma A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Ascendis Pharma A/S011102.92

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 52.69%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Ascendis Pharma A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
Ascendis Pharma A/S$14.98 million441.02$-244,180,000.00($5.25)-23.41

Pandion Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S.

Profitability

This table compares Pandion Therapeutics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Summary

Pandion Therapeutics beats Ascendis Pharma A/S on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and TG Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
TG Therapeutics00503.00

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 39.37%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and TG Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
TG Therapeutics$150,000.0043,038.06$-172,870,000.00($1.83)-25.09

Pandion Therapeutics has higher revenue and earnings than TG Therapeutics.

Profitability

This table compares Pandion Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
TG Therapeutics-151,798.69%-223.96%-108.08%

Summary

TG Therapeutics beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Ionis Pharmaceuticals27602.27

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 41.14%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Ionis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
Ionis Pharmaceuticals$1.12 billion5.12$303.26 million$2.0819.61

Ionis Pharmaceuticals has higher revenue and earnings than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
Ionis Pharmaceuticals7.82%6.57%3.39%

Summary

Ionis Pharmaceuticals beats Pandion Therapeutics on 9 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 65.4% of Allakos shares are owned by institutional investors. 44.8% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Allakos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Allakos00403.00

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 72.32%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Allakos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
AllakosN/AN/A$-85,370,000.00($1.89)-55.73

Pandion Therapeutics has higher revenue and earnings than Allakos.

Profitability

This table compares Pandion Therapeutics and Allakos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
AllakosN/A-29.18%-27.70%

Summary

Allakos beats Pandion Therapeutics on 5 of the 9 factors compared between the two stocks.


Pandion Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.56flat$7.06 billion$87.99 million-80.43News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90flat$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$122.91flat$6.67 billion$14.98 million-14.97Analyst Downgrade
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.92flat$6.44 billion$150,000.00-21.66Unusual Options Activity
News Coverage
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78flat$5.74 billion$1.12 billion84.96
Allakos logo
ALLK
Allakos
1.7$105.33flat$5.74 billionN/A-38.44Insider Selling
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80flat$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.5$41.62flat$5.56 billion$4.84 billion-693.55
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20flat$5.52 billion$66.51 million17.56Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$78.18flat$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.15flat$5.19 billion$1.00 billion-11.99Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.56flat$4.70 billionN/A-6.08Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$76.13flat$4.41 billion$6.87 million-7.36Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25flat$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64flat$4.16 billion$1.11 billion24.96Analyst Report
I-Mab logo
IMAB
I-Mab
1.2$57.00flat$4.11 billion$4.31 million-1.97Increase in Short Interest
Gap Up
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90flat$3.98 billion$806.43 million-9.33Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.28flat$3.84 billion$117.91 million-11.01
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.83flat$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57flat$3.66 billionN/A-6.14Analyst Report
Analyst Revision
News Coverage
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03flat$3.58 billionN/A-20.81Analyst Report
Insmed logo
INSM
Insmed
1.2$32.62flat$3.47 billion$136.47 million-12.55
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00flat$3.46 billion$114.62 million-7.66Analyst Report
LEGN
Legend Biotech
1.2$26.00flat$3.46 billion$64.39 million0.00Decrease in Short Interest
Gap Down
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.14flat$3.39 billion$339.08 million-12.29Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.96flat$3.39 billion$306.98 million-7.00
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87flat$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.37flat$3.29 billion$36.13 million-70.70
Arvinas logo
ARVN
Arvinas
1.5$64.69flat$3.16 billion$42.98 million-25.27
Alkermes logo
ALKS
Alkermes
1.2$19.65flat$3.15 billion$1.17 billion-42.72
MorphoSys logo
MOR
MorphoSys
0.3$22.75flat$3.05 billion$80.43 million108.34Decrease in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60flat$3.04 billionN/A-56.02Insider Selling
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$62.88flat$2.91 billion$421.03 million22.14Analyst Report
Insider Selling
News Coverage
Gap Up
OPKO Health logo
OPK
OPKO Health
1.9$4.34flat$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64flat$2.89 billion$644.77 million-10.79
Organogenesis logo
ORGO
Organogenesis
1.0$21.22flat$2.89 billion$260.98 million-353.67
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$10.10flat$2.73 billion$182.24 million-8.78Analyst Upgrade
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.18flat$2.72 billion$25 million-9.04Insider Selling
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.67flat$2.71 billionN/A-23.99
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.77flat$2.67 billion$306.49 million25.58
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$31.28flat$2.62 billion$60,000.00-9.71
Xencor logo
XNCR
Xencor
1.2$42.78flat$2.59 billion$156.70 million-30.56
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.88flat$2.57 billion$2.11 million-8.85Analyst Report
Analyst Revision
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.23flat$2.50 billion$120.28 million-151.75Analyst Report
Decrease in Short Interest
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.76flat$2.48 billion$15 million-17.68Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.50flat$2.42 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57flat$2.35 billion$33.94 million-88.91Gap Up
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22flat$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.33flat$2.18 billion$23.90 million-18.22Analyst Report
Unusual Options Activity
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$49.10flat$2.06 billionN/A0.00Insider Selling
Analyst Revision
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.